• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.62
  • VXN 16.44
  • VXO 14.46
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company offers RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation in advanced illness patients receiving palliative care. It is also conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as in blood vessels supplying other solid tumors. In addition, the company is developing therapeutic vaccines designed to stimulate an immune response to PSMA; PRO 140, a viral-entry inhibitor for human immunodeficiency virus (HIV), which is in Phase II clinical testing; and novel multiplex PI3-Kinase inhibitors to combat aggressive forms of cancer. Additionally, it engages in researching a prophylactic vaccine for HIV infection; and candidates that are HCV-entry inhibitors. The company was founded in 1986 and is based in Tarrytown, New York.

NO
     
PGNX (Progenics Pharmaceuticals Inc)
Last Trade 5.12 Date 12/7/2019
Change % 2.61 % Price Change 0.13
Open 5.04 52 Week High 6.31
High 5.17 52 Week Low 3.42
Low 5.04 Type stock
Volume 590647 Average Volume 1156109
Prev Close 4.99 Stock Exchange NASDAQ
Bid 4.81 Ask 5.27
Bid Size 5 Ask Size 2
1st Yr Estimated EPS Growth 0.1777 2nd Yr Estimated EPS Growth -0.3897
2 Years Forward Earning Yield -0.1162 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -6.8567 2 Years EV/Forward EBITDA -6.9301
Book Value per Share 0.6473 Book Value Yield 0.1264
Buy Back Yield 0.0 CAPE Ratio
Cash Return -0.1782 Cash Flow per Share -0.7608
Cash Flow Yield -0.1486 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.1641 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -4.6804 EV / Forward EBITDA -4.7116
EV / Forward Revenue 12.3818 EV / Pre Tax Income
EV / Revenue 18.8171 EV / Total Asset 3.342
Expected Dividend Growth Rate Free Cash Flow per Share -0.9098
Free Caash Flow Ratio Free Cash Flow Yield -0.1777
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1904 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 7.910306 PB Ratio 10 Year Growth 0.201723
PB Ratio 3 Year Growth 6.397722 Cash Ratio 3 Year Average 482.5715
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 74.869906 PE Ratio 10 Year Growth
PE Ratio 10 Year High 170.6 PE Ratio 10 Year Low 12.327869
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 63.293948
PE Ratio 5 Year Avg 85.400438 PE Ratio 5 Year High 170.6
PE Ratio 5 Year Low 34.0625 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 67.602973 Price Change 1 Month 0.980843
Price to Cash Ratio 6.860881 Price / EBITDA
Price to Sales Ratio 18.874708 Price to Sales Ratio 10 Year Growth 0.191096
Price to Sales Ratio 3 Year Avg 23.229836 Price to Sales Ratio 5 Year Avg 85.400438
Sale per Share 0.2713 Sales Yield 0.053
Sustainable Growth Rate -0.8428 Tangible Book Value per Share 0.3586
Tangible Book Value per Share 3 year Avg 0.7706 Tangible Book Value per Share 5 year Avg 0.9142
Total Asset per Share 1.5049 Total Yield 0.0
Working Capital per Share 0.644 Working Capital per Share 3 Year Avg 1.4119
Working Capital per Share 5 Year Avg 1.4576 Beta 2.00621
12